De novo malignancies following renal transplantation
As renal transplantation is being increasingly undertaken for growing numbers of patients with end-stage renal disease, there has been a trend toward offering this treatment to patients who have undergone successful treatment for malignant disease. Malignancies following immunosuppressive therapy have been observed at all transplantation centers and much material has been published on this subject in recent years [1–8].
KeywordsGraft Survival Renal Transplant Recipient Transplant Proc Kidney Transplant Recipient Graft Survival Rate
Unable to display preview. Download preview PDF.
- 2.Penn I. Why do immunosuppressed patients develop cancer?, in Pimentel E (ed): CRC Critical reviews in oncogenesis. Boca Raton, FL, CRC, 1989; 27–52.Google Scholar
- 3.Penn I. Post-transplant kidney cancers and skin cancers (including Kaposi’s sarcoma), in Schmahl D, Penn I (eds): Cancer in organ transplant recipients. New York, NY, Springer-Verlag, 1991; 46–53.Google Scholar
- 4.Penn I. Immunosuppression-A contributory factor in lymphoma formation. Clin Transplant 1992; 6:214–219.Google Scholar
- 5.Penn I. Immunosuppression and opportunistic tumors: Do viruses play a role?, in Dammacco F (ed): Advances in tumor immunology and allergic disorders. Immuno Incontri, Milan, Italy, Edi Ermes, 1992; 139–162.Google Scholar
- 8.Shel AJR. Development of malignancy following renal Transplantation in Australia and New Zealand. Transplant Proc, 1992; 24: 1275.Google Scholar
- 9.Oka T, Ohmori Y, Aikawa I et al. Early conversion of CsA to Az in living related renal transplantation. Transplant Proc, 1989; 21: 1645–1648.Google Scholar